<?xml version='1.0' encoding='utf-8'?>
<document id="15851915"><sentence text="Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children."><entity charOffset="18-27" id="DDI-PubMed.15851915.s1.e0" text="lopinavir" /><entity charOffset="28-37" id="DDI-PubMed.15851915.s1.e1" text="ritonavir" /><entity charOffset="54-63" id="DDI-PubMed.15851915.s1.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.15851915.s1.e0" e2="DDI-PubMed.15851915.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s1.e0" e2="DDI-PubMed.15851915.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s1.e0" e2="DDI-PubMed.15851915.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s1.e1" e2="DDI-PubMed.15851915.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s1.e1" e2="DDI-PubMed.15851915.s1.e2" /></sentence><sentence text="Nucleoside reverse transcriptase inhibitor-sparing regimens have not yet been systematically evaluated in children" /><sentence text=" The nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz lower plasma levels of protease inhibitors in adults and children"><entity charOffset="52-62" id="DDI-PubMed.15851915.s3.e0" text="nevirapine" /><entity charOffset="67-76" id="DDI-PubMed.15851915.s3.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.15851915.s3.e0" e2="DDI-PubMed.15851915.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s3.e0" e2="DDI-PubMed.15851915.s3.e1" /></sentence><sentence text=" Therefore, coadministration of lopinavir/ritonavir with nevirapine and efavirenz necessitates a 30% increase in the dose of lopinavir/ritonavir in adults"><entity charOffset="32-41" id="DDI-PubMed.15851915.s4.e0" text="lopinavir" /><entity charOffset="42-51" id="DDI-PubMed.15851915.s4.e1" text="ritonavir" /><entity charOffset="57-67" id="DDI-PubMed.15851915.s4.e2" text="nevirapine" /><entity charOffset="72-81" id="DDI-PubMed.15851915.s4.e3" text="efavirenz" /><entity charOffset="125-134" id="DDI-PubMed.15851915.s4.e4" text="lopinavir" /><entity charOffset="135-144" id="DDI-PubMed.15851915.s4.e5" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e0" e2="DDI-PubMed.15851915.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e0" e2="DDI-PubMed.15851915.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e0" e2="DDI-PubMed.15851915.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e0" e2="DDI-PubMed.15851915.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e0" e2="DDI-PubMed.15851915.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e0" e2="DDI-PubMed.15851915.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e1" e2="DDI-PubMed.15851915.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e1" e2="DDI-PubMed.15851915.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e1" e2="DDI-PubMed.15851915.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e1" e2="DDI-PubMed.15851915.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e1" e2="DDI-PubMed.15851915.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e2" e2="DDI-PubMed.15851915.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e2" e2="DDI-PubMed.15851915.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e2" e2="DDI-PubMed.15851915.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e2" e2="DDI-PubMed.15851915.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e3" e2="DDI-PubMed.15851915.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e3" e2="DDI-PubMed.15851915.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e3" e2="DDI-PubMed.15851915.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e4" e2="DDI-PubMed.15851915.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15851915.s4.e4" e2="DDI-PubMed.15851915.s4.e5" /></sentence><sentence text=" In children, the extent of the pharmacokinetic interaction between efavirenz and lopinavir/ritonavir has not yet been studied"><entity charOffset="68-77" id="DDI-PubMed.15851915.s5.e0" text="efavirenz" /><entity charOffset="82-91" id="DDI-PubMed.15851915.s5.e1" text="lopinavir" /><entity charOffset="92-101" id="DDI-PubMed.15851915.s5.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.15851915.s5.e0" e2="DDI-PubMed.15851915.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s5.e0" e2="DDI-PubMed.15851915.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s5.e0" e2="DDI-PubMed.15851915.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s5.e1" e2="DDI-PubMed.15851915.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s5.e1" e2="DDI-PubMed.15851915.s5.e2" /></sentence><sentence text="" /><sentence text="To investigate the pharmacokinetics of increased-dose (300/75 mg/m2 twice-daily) lopinavir/ritonavir with normal-dose (14 mg/kg once-daily) efavirenz in HIV-1-infected children"><entity charOffset="81-90" id="DDI-PubMed.15851915.s7.e0" text="lopinavir" /><entity charOffset="91-100" id="DDI-PubMed.15851915.s7.e1" text="ritonavir" /><entity charOffset="140-149" id="DDI-PubMed.15851915.s7.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.15851915.s7.e0" e2="DDI-PubMed.15851915.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s7.e0" e2="DDI-PubMed.15851915.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s7.e0" e2="DDI-PubMed.15851915.s7.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s7.e1" e2="DDI-PubMed.15851915.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s7.e1" e2="DDI-PubMed.15851915.s7.e2" /></sentence><sentence text="" /><sentence text="Steady-state pharmacokinetics of lopinavir and efavirenz were determined and compared with historical data"><entity charOffset="33-42" id="DDI-PubMed.15851915.s9.e0" text="lopinavir" /><entity charOffset="47-56" id="DDI-PubMed.15851915.s9.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.15851915.s9.e0" e2="DDI-PubMed.15851915.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s9.e0" e2="DDI-PubMed.15851915.s9.e1" /></sentence><sentence text="" /><sentence text="Fifteen children of median age 11" /><sentence text="8 (range, 5" /><sentence text="7-16" /><sentence text="3) years were included" /><sentence text=" Area under the plasma concentration-time curve (AUC0-12), peak levels (Cmax), and trough levels (Cmin) of lopinavir were similar to historical data in adults and children"><entity charOffset="107-116" id="DDI-PubMed.15851915.s15.e0" text="lopinavir" /></sentence><sentence text=" Medians (interquartile range) were 92" /><sentence text="3 (43" /><sentence text="5-138" /><sentence text="5) mg/L" /><sentence text="h, 12" /><sentence text="5 (6" /><sentence text="9-16" /><sentence text="7) mg/L, and 5" /><sentence text="7 (1" /><sentence text="3-8" /><sentence text="0) mg/L, respectively" /><sentence text=" Efavirenz pharmacokinetics approximated previous data in adults and children"><entity charOffset="1-10" id="DDI-PubMed.15851915.s27.e0" text="Efavirenz" /></sentence><sentence text="" /><sentence text="The increased dose of 300/75 mg/m2 twice-daily lopinavir/ritonavir compensates for the enzyme-inducing effect of efavirenz in HIV-infected children"><entity charOffset="47-56" id="DDI-PubMed.15851915.s29.e0" text="lopinavir" /><entity charOffset="57-66" id="DDI-PubMed.15851915.s29.e1" text="ritonavir" /><entity charOffset="113-122" id="DDI-PubMed.15851915.s29.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.15851915.s29.e0" e2="DDI-PubMed.15851915.s29.e0" /><pair ddi="false" e1="DDI-PubMed.15851915.s29.e0" e2="DDI-PubMed.15851915.s29.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s29.e0" e2="DDI-PubMed.15851915.s29.e2" /><pair ddi="false" e1="DDI-PubMed.15851915.s29.e1" e2="DDI-PubMed.15851915.s29.e1" /><pair ddi="false" e1="DDI-PubMed.15851915.s29.e1" e2="DDI-PubMed.15851915.s29.e2" /></sentence><sentence text="" /></document>